Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trinity Biotech, a developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, has launched its new high throughput haemostasis analyzer, the Destiny Max, in Europe.
Subscribe to our email newsletter
According to the company, the target market for the instrument includes university hospitals, high throughput general hospitals, high volume commercial laboratories and reference laboratories.
Ronan Caoimh, CEO of Trinity Biotech, said: “I am particularly pleased to announce the launch of Destiny Max which is without doubt the best haemostasis instrument offering available on the market. The instrument will enable Trinity to target the high throughput segment of the laboratory based haemostasis market which represents approximately 50% of the overall market or $500 million annually.
“The project has definitively proven our ability to integrate hardware, software and reagents into a new instrument platform that will exceed customer expectations. Initial sales of the instrument will take place this month to Japan, Italy and Ireland.”